CereVasc, Inc., which is developing the eShunt System for the treatment of communicating hydrocephalus, has secured $85.0M in Series C funding. This substantial capital infusion will advance the company's work on its novel device, designed to address one of the most common neurological conditions affecting both children and adults.
The Series C round underscores continued momentum for CereVasc as it progresses with the eShunt System. The device aims to provide a new therapeutic option for patients with communicating hydrocephalus, a condition impacting a broad demographic.
